Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 6/20 | 0.73 |
| ▸ | SRD5A2 | P31213 | 6/20 | 0.73 |
| ▸ | CNR2 | P34972 | 9/20 | 0.59 |
| ▸ | CNR1 | P21554 | 6/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9544353 | 0.95 | SRD5A1 (0.68) | SRD5A1SRD5A2CNR2CNR1 | |
| SCHEMBL9544630 | 0.94 | SRD5A1 (0.71) | SRD5A1SRD5A2CNR2CNR1 | |
| SCHEMBL9543204 | 0.93 | SRD5A1 (0.70) | SRD5A1SRD5A2CNR2CNR1 | |
| SCHEMBL9544705 | 0.93 | SRD5A1 (0.70) | SRD5A1SRD5A2CNR2CNR1 | |
| SCHEMBL9545397 | 0.93 | SRD5A1 (0.70) | SRD5A1SRD5A2CNR2CNR1 | |
| SCHEMBL9543311 | 0.90 | CNR1 (0.61) | SRD5A1SRD5A2CNR2CNR1POLB | |
| SCHEMBL9544332 | 0.86 | CNR1 (0.57) | SRD5A1SRD5A2CNR2CNR1POLB | |
| SCHEMBL9338204 | 0.85 | SRD5A1 (0.73) | SRD5A1SRD5A2CNR2CNR1KMT2A | |
| SCHEMBL9543728 | 0.84 | CNR1 (0.59) | SRD5A1SRD5A2CNR2CNR1POLB | |
| SCHEMBL9441222 | 0.84 | SRD5A1 (0.80) | SRD5A1SRD5A2CNR2CNR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1993016996-A1 | INDOLE DERIVATIVES AS TESTOSTERONE-5-ALPHA-REDUCTASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-09-02 | — | — | WO | disclosed |